Cover Image
市場調查報告書

雷特氏症候群:開發中產品分析

Rett Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359401
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
雷特氏症候群:開發中產品分析 Rett Syndrome - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 122 Pages
簡介

本報告提供雷特氏症候群治療藥的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

雷特氏症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

雷特氏症候群:企業開發中的治療藥

雷特氏症候群:大學/機關研究中的治療藥

雷特氏症候群:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

雷特氏症候群:企業開發中的產品

雷特氏症候群:大學/機關研究中的產品

雷特氏症候群的治療藥開發企業

  • Anavex Life Sciences Corp.
  • ArmaGen Inc.
  • Edison Pharmaceuticals, Inc.
  • GW Pharmaceuticals Plc
  • 田邊三菱製藥
  • Neuren Pharmaceuticals Limited
  • Neurolixis Inc.
  • Newron Pharmaceuticals S.p.A.
  • OPKO Health, Inc.
  • Oryzon Genomics S.A.
  • PharmatrophiX, Inc.
  • Raptor Pharmaceutical Corp.
  • Sage Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.

雷特氏症候群:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

雷特氏症候群:最近的開發平台趨勢

雷特氏症候群:暫停中的計劃

雷特氏症候群:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8597IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H2 2016, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 3, 8, 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively for Rett Syndrome.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rett Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Rett Syndrome - Overview
    • Pipeline Products for Rett Syndrome - Comparative Analysis
  • Rett Syndrome - Therapeutics under Development by Companies
  • Rett Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Rett Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Rett Syndrome - Products under Development by Companies
  • Rett Syndrome - Products under Investigation by Universities/Institutes
  • Rett Syndrome - Companies Involved in Therapeutics Development
    • Anavex Life Sciences Corp.
    • ArmaGen Inc.
    • Edison Pharmaceuticals, Inc.
    • Eloxx Pharmaceuticals, Ltd.
    • GW Pharmaceuticals Plc
    • Mitochon Pharmaceuticals, Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Neuren Pharmaceuticals Limited
    • Neurolixis Inc.
    • Newron Pharmaceuticals S.p.A.
    • OPKO Health, Inc.
    • Oryzon Genomics SA
    • PharmatrophiX, Inc.
    • Raptor Pharmaceutical Corp.
    • Recursion Pharmaceuticals, LLC
    • Sage Therapeutics, Inc.
    • Ultragenyx Pharmaceutical Inc.
  • Rett Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • amlexanox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bryostatin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPT-157633 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteamine DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • desipramine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELX-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fingolimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene therapy to Activate MECP2 for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22A4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide For Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORY-2001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REV-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sarizotan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trofinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rett Syndrome - Dormant Projects
  • Rett Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Jun 24, 2016: Neuren presents at the Rettsyndrome.org 2016 Research Symposium
      • Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders
      • Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
      • May 20, 2016: Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
      • May 17, 2016: Mitochon Pharmaceuticals Raises $1.6M for Clinical Stage Development
      • Apr 07, 2016: First subject commences Neuren's pediatric Rett syndrome Phase 2 trial
      • Feb 25, 2016: Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome
      • Oct 13, 2015: Rettsyndrome.org confirms financial support for Neuren's clinical trials of trofinetide
      • Oct 12, 2015: Neuren receives Notice of Allowance for new US patent covering the use of trofinetide to treat Rett syndrome
      • Aug 14, 2015: "trofinetide" confirmed as the International Nonproprietary Name for Neuren's NNZ-2566
      • Aug 13, 2015: Neuren confirms orphan drug designation in Europe for Rett syndrome and Fragile X syndrome
      • Jul 29, 2015: Neuren reports progress in orphan drug programs
      • Nov 12, 2014: Neuren's NNZ-2566 successful In Demonstrating Clinical Benefit In Rett syndrome Phase 2 trial
      • Dec 24, 2012: Neuren Pharma Receives FDA Approval For Phase II trial Of NNZ-2566 In Rett Syndrome
      • May 17, 2012: Neuren Holds Pre-IND Meeting On Proposed Rett Syndrome Clinical Trials With FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rett Syndrome, H2 2016
  • Number of Products under Development for Rett Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Rett Syndrome - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Rett Syndrome - Pipeline by ArmaGen Inc., H2 2016
  • Rett Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H2 2016
  • Rett Syndrome - Pipeline by Eloxx Pharmaceuticals, Ltd., H2 2016
  • Rett Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Rett Syndrome - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Rett Syndrome - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Rett Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
  • Rett Syndrome - Pipeline by Neurolixis Inc., H2 2016
  • Rett Syndrome - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
  • Rett Syndrome - Pipeline by OPKO Health, Inc., H2 2016
  • Rett Syndrome - Pipeline by Oryzon Genomics SA, H2 2016
  • Rett Syndrome - Pipeline by PharmatrophiX, Inc., H2 2016
  • Rett Syndrome - Pipeline by Raptor Pharmaceutical Corp., H2 2016
  • Rett Syndrome - Pipeline by Recursion Pharmaceuticals, LLC, H2 2016
  • Rett Syndrome - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Rett Syndrome - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rett Syndrome - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Rett Syndrome, H2 2016
  • Number of Products under Development for Rett Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top